050 - Acasti Pharma's Novel Omega-3 Formulation Steps Up!

Hey everybody, we made it to #50! In this episode, I chat with Nathan Weinstein from Aegis Capital about Acasti Pharma. We discuss the omega-3 space and Acasti's EPA/DHA formulation called CaPre. Acasti is seeking the approval of CaPre for the indication of severe hypertriglyceridemia and has two pivotal catalysts at the end of the year, which will be massive movers for the stock. Amarin's upcoming catalysts are also likely to affect them. Check out the whole video for more details!

Relevant links:



*this is not investment advice*
Follow me on twitter @matthewlepoire

#breakingbiotech #acst #amrn

biotechnology,biotechnology trading,money,how to make money,biotech,biotech trading,trading,investments,biotech investing,biotechnology investing,acst,acast,amarin,vascepa,dha,epa,fish oil,omega-3,omega 3,free fatty acids,phospholipids,capre,acasti,acasti pharma,